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There is increasing statistical evidence that the presence of tumour cells in bone marrow detected by immunocytochemistry
represents an important prognostic indicator in breast cancer, but their individual capacity to become clinical metastases is unknown.
The aim of this study was to assess the proliferative capacity of these occult metastatic cells in the bone marrow of patients with
various stages of breast cancer. We obtained bone marrow aspirates from 60 patients with breast cancer before treatment with
chemotherapy: 17 stage II, 12 stage III and 31 stage IV. After bone marrow culture for 6–34 days (median: 17 days) under specific cell
culture conditions, viable epithelial cells were detected by cytokeratin staining in 40 patients (66%). Expansion of tumour cells was
poorly correlated with tumour cell detection on primary screening (P¼0.06). There was a nonsignificant correlation between the
number and the presence of expanded tumour cells and the UICC stage of the patients. On primary screening, tumour cell detection
was positive in 56% of patients and was correlated with clinical UICC stage (P¼0.01). However, with a median follow-up of 23
months, expansion of tumour cells from bone marrow was associated with decreased patient survival (P¼0.04), whereas the survival
difference according to detection of CK-positive cells on primary screening was not statistically significant. In conclusion, viable tumour
cells can be detected in the bone marrow of breast cancer patients. Their proliferative potential could be predictive of outcome and
deserves further investigation.
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The clinical importance of occult tumour cells in the bone marrow
of breast cancer patients has been demonstrated in several
prospective studies, and represents an independent prognostic
factor for distant relapse and overall survival (Harbeck et al, 1994;
Diel et al, 1996; Mansi et al, 1999; Braun et al, 2000b; Gebauer et al,
2001; Gerber et al, 2001). Immunocytochemical (ICC) detection of
epithelial cells in the bone marrow of breast cancer patients has
been performed with a variety of antibodies, but the specificity and
clinical relevance of the markers used to characterise epithelial
cells remain controversial (Braun et al, 1998; Funke and Schraut,
1998). However, the simple detection of CK-positive cells does not
provide any information about the proliferative potential of
disseminated cancer cells. No marker is available to differentiate
between cells that will die, those in a quiescent state and those with
metastatic and proliferative potentials. Very little is known about
the biological features of these cells. Currently available data
suggest that CK-positive cells in bone marrow aspirates of cancer
patients represent a selected, but nevertheless heterogeneous
population of dormant (G0-phase) cancer cells (Braun and Pantel,
1999). Only a small fraction of disseminated tumour cells in bone
marrow expressed a proliferative marker (Ki-67 or p120) in
double-staining studies (Pantel et al, 1993). The dormant state of
these cells may be one explanation for the relative resistance of
micrometastatic tumour cells to chemotherapy (Braun et al,
2000a).
In a recent study, Solakoglu et al (2002) cultured bone marrow
samples from 153 patients with various types of carcinoma (breast,
prostate, colon and kidney). Viable epithelial cells were detected by
cytokeratin staining in 81% of patients with no known distant
metastases. Marked expansion of tumour cells was also correlated
with decreased patient survival. Extensive cell culture experiments
have also shown that cells disseminating into bone marrow have a
time-limited proliferative potential (Pantel et al, 1995).
The present study is an attempt to investigate the clinical
relevance of the in vitro proliferative potential of CK-positive
tumour cells by culturing under specific tissue culture conditions
and to compare the detection of these expended cells to ‘standard’
ICC detection in bone marrow using anticytokeratin antibodies.
PATIENTS AND METHODS
Patients
Sixty consecutive patients with primary or metastatic breast cancer
were included in the study between 1999 and 2001 after giving their
written informed consent. All patients were treated at the Institut
Curie and follow-up data were obtained prospectively. The Received 10 January 2003; revised 28 April 2003; accepted 7 May 2003
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yclinicopathological data and information concerning treatment
modalities of the patients are summarised in Table 1. Their median
age was 52 years (range: 36–74 years). Histology showed 51 ductal,
eight lobular, one apocrine and one undifferentiated carcinomas.
Forty-one tumours were hormone receptor positive, 15 were
negative and four were undetermined. UICC stages were 17 stage
II, 12 stage III and 31 stage IV. TUICC classification of tumour
sizes for nonmetastatic patients was three T1, 12 T2, two T3, four
T4 not d, and six inflammatory breast cancers (T4d). Bone marrow
sampling was performed in 14 patients before neoadjuvant
chemotherapy, in 12 before adjuvant chemotherapy, based on
four to six cycles of docetaxel–doxorubicin or epirubicin,
cyclophosphamide 75FU. Only three nonmetastatic patients did
not receive adjuvant chemotherapy. The median follow-up was 23
months (range: 13–31 months) after sampling. Bone marrow
aspirates (4–5ml per sample) were obtained from both anterior
iliac crests preoperatively in five patients or before starting
chemotherapy (neoadjuvant or for metastatic disease) in 55
patients. One bone marrow aspirate was obtained under local
anaesthesia from the posterior iliac crest (39 patients including all
the stage IV patients) or by sternal tap (4–5ml per sample) (16
patients).
Bone marrow preparation
Three to five millilitres of bone marrow aspirate were collected and
stored on EDTA (Vacutainer). Components of the bone marrow
aspirate were processed under laminar flow. Each sample was
diluted in Hanks (Gibco Brl UK) and separated by Ficoll/Hypaque
density centrifugation (Sigma; density, 1.077gml
 1) in Leucosep
tubes (Polylabo) (830g, 15min, 201C). The mononuclear cell
(MNC) layer was harvested from each tube, combined, diluted in
Hanks and centrifuged at 360g, 5min at 201C in a 50ml conical
tube. The cells were resuspended in PBS solution þ0.1% BSA
(bovine serum albumin). Cell counts were performed on aliquots
diluted in 3% acetic acid for red cell lysis. An aliquot of aspirate
was tested for the presence of CK-positive tumour cells (primary
screening). The remaining bone marrow cells were cultured and
then rescreened for CK expression (culture screening).
Primary screening
Mononuclear cells were resuspended at 1 10
6ml
 1. One millilitre
of the cell suspension (approximately 10
6 cells) was cytocentri-
fuged onto polylysinated slides at 580g twice for 3min (Hettich
Universal 16A cytocentrifuge) (Schwartz, 1991). The supernatant
was carefully removed from each slide after the first cytocen-
trifugation and the slides were allowed to dry in air overnight.
Slides were stored at room temperature before staining or were
stored at  201C and then at  801C until staining.
Cell culture and culture screening
Bone marrow cells were cultured as described by Pantel et al
(1995) and Solakoglu et al (2002). MNCs (1 10
7 to 3 10
7) were
initially plated in culture flasks coated with an extracellular matrix
(Paesel & Lorei, Frankfurt, Germany). The culture medium
contained RPMI 1640 supplemented with 10% FCS, 10mgml
 1
transferrin, 5mgml
 1 insulin, 2mM glutamine, 10ngml
 1 basic
Fibroblastic Growth Factor (Boehringer Mannheim, Germany) and
10ngml
 1 recombinant human epidermal growth factor (Boeh-
ringer Mannheim, Germany). The cells were cultured under 5%
CO2 and reduced oxygen (4%). Before confluence, the adherent
cells (including the epithelial tumour cells) were removed by
trypsination. To determine the number of CK-positive cells, an
aliquot containing 1 to 30 10
5 cells was centrifuged onto glass
slides and immunocytochemically stained (culture screening)
using the method described above. In some cases, cells were
Table 1 Patient characteristics
Positive primary screening Positive culture screening
N¼60 No. % No. % P No. % P
Age (year), median, range 52 (36–74) 52 vs 52.7 0.74* 52 vs 52 0.98*
Menopausal status
Pre 32 54 18 56 0.94 22 69 0.71
Post 28 46 16 57 18 64
Clinical stage (UICC)
II 17 28 5 29.5 0.01 9 53 0.33
III 12 20 6 50 8 66.6
IV 31 52 23 74.2 23 74.2
Hormonal status
a
ER+ 39 65 21 54 0.60 25 64 0.88
ER  18 30 11 61 12 67
Unknown 3 5
PR+ 19 32 13 68 0.55 15 79 0.24
PR  24 40 12 50 15 62.5
Unknown 17 28
Histology
a
Ductal 51 83 30 59 0.42 33 65 0.43
Others 9 17 4 5 7 8
Tumour grade
a
I 6 10 4 66 0.36 4 66 0.80
II 23 38 15 65 16 70
III 20 33 9 45 12 60
Unknown 11 18
*Student’s t-test.
aAt initial diagnosis.
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ytransferred into new flasks. Two to three slides were stained with
A45 B/B3 and one to two slides were used as controls with
irrelevant IgG1. The number of in vitro expanded CK-positive cells
was calculated: number of CK cells detected on slides after
trypsination on culture screening according to the total number of
MNCs per slide (from 10
4 to 10
5) divided by the total number of
MNCs cultured at the time of sample collection. Results are
expressed as the number of CK cells/10
6 MNCs.
Immunocytochemical staining
The pancytokeratin (CK) monoclonal antibody A45-B/B3 (Micro-
met, Germany and Chromavision, USA), which recognises several
cytokeratin epitopes CK 8, CK 18 and CK 19, was applied for
epithelial cell detection (Stigbrand et al, 1998). The immunostain-
ing procedure was standardised by using a Cadenza (Shandon)
automat. Before staining, cytospots were fixed with 4% parafor-
maldehyde for 5min then dried for 15min at room temperature.
Endogenous alkaline phosphatase was then blocked with TBS
solution with 2% AB serum (15min) (Sanofi Diagnostics Pasteur,
USA) and 2% levamisole. This solution was used to dilute primary
and secondary antibodies. After blocking, the slides were
incubated with the primary antibody A45 B/B3 for 40min
(2mgml
 1). Control slides were incubated under the same
conditions with a mouse monoclonal anti-FITC IgG1 (one out of
1250) (Sigma Immuno Chemicals, USA). Slides were incubated for
20min with secondary polyclonal rabbit anti-mouse antibody
(Dako, USA). After each step, the slides were rinsed for 5min in
TBS 1  solution. Immune complexes were revealed by the
alkaline phosphatase-anti-alkaline phosphatase technique (Dako,
USA) (one out of 50) for 25min (Cordell et al, 1984). The
chromogenic reaction was performed for 20min with a colori-
metric substrate of Fuchsin solution (2.5% in 2 N HCl) (New
Fuchsin, Sigma) with 4% NaNO2,8 %b-naphthol (Sigma, USA) and
2% levamisole (Dako, USA). Cells were counterstained with
Mayer’s haematoxylin (1min) (Sigma, USA) diluted to 1:3 in
distilled water. The specimen was then rinsed under running water
for 5min and then in TBS. Slides were coverslipped using
Faramount mounting medium (Dako, USA). Mononuclear cells
(3 10
6) were evaluated for each patient and for each bone
marrow sample. Negative controls, stained with anti-FITC mono-
clonal mouse antibody, were performed on an equivalent number
of cells (i.e. three slides, 3 10
6 MNCs) for each patient.
Positive controls were obtained with bone marrow from normal
donors undergoing orthopaedic surgery (Cochin Hospital), spiked
with SKBR3 or MCF7 cell lines, 10–10
2 for 10
6 MNCs per cytospot.
One positive control slide and one negative control slide were
added to each series of 20 stained slides in the automated device.
CK-positive cell detection by digital microscopy
The ACIS (ChromaVision Medical Systems, Inc.). is a compu-
terised microscope, which includes an image processing system
that has been optimised for the detection of rare carcinoma cells in
specimens (Bauer et al, 2000). The application software supplied
with the instrument starts by scanning a microscope slide at low
magnification ( 10). The instrument then returns to objects
originally identified by their stain for a second analysis at higher
magnification ( 40 or  60). In this case, more sophisticated
image analysis of colour and morphometric characteristics is
performed in order to exclude cellular debris, large clumps and
cells with morphological features typical of normal haematological
MNCs as opposed to CK-positive carcinoma cells. Cellular objects
that meet colour- and morphometry-based criteria for probable
tumour cells are collected and presented as montage images for
review and classification by a pathologist or another investigator
(JYP). Criteria for evaluation of immunostained cells in bone
marrow were adapted from Borgen et al (1999) based on the results
of the European ISHAGE Working Group for standardisation of
tumour cell detection.
Statistical methods
Patient characteristics were prospectively recorded on the Institut
Curie medical files. Differences between treatment groups were
analysed by w
2 tests for categorical variables and t-tests for
continuous variables, and the Kruskal–Wallis test was used for
nonparametric comparisons. Survival time and disease-free
survival time were measured from the date of bone marrow
aspiration until the date of death or last follow-up. Survival curves
were determined using a Kaplan–Meier product-limit method
(Kaplan and Meier, 1958). Statistical significance between groups
was assessed using the log-rank test. Statistical analyses were
performed by Statview software (SAS Institute Inc., 1998).
RESULTS
Expansion of bone marrow cells
From August 1999 to March 2001, 60 bone marrow samples were
successfully cultured. Cultures were stopped between 6 and 34 days
(median: 17 days). An example of positive results is given in
Figure 1 and Figure 2. No correlation was observed between the
number of CK-positive cells detected in the bone marrow sample
(primary screening) and the number of CK-positive cells in the
culture screening (P¼0.19). Thirty-four (56%) patients presented
a positive primary screening result, while 40 (66%) of these
patients presented a positive culture screening result. CK-positive
cell detection on primary screening was not strongly correlated
with detection on culture screening (P¼0.06). Fourteen cases
(23%) initially negative on primary screening became positive on
culture screening. Inversely, eight cases classified as positive on the
initial screening, failed to produce any CK-positive cells (13%) on
culture screening (Table 2).
Correlation with tumour stage
The correlation between primary screening and tumour stage was
statistically significant. Among the 34 patients with detectable CK-
positive cells on primary screening, five of 17 (29%) had stage II
tumours, six of 12 (50%) had stage III tumours and 23 of 31 (74%)
had stage IV tumours, according to the UICC classification
(International Union Against Cancer) (w
2 test, P¼0.01). As shown
in Table 3, the number of CK-positive cells on initial screening was
correlated with UICC stage (P¼0.0013). No significant correlation
was observed between the results of culture screening and tumour
stage (P¼0.21) (Table 3). Tumour cell expansion was not
correlated with hormonal receptor status (P¼0.88) or histology
(ductal vs lobular) (P¼0.43) or tumour grade (P¼0.80) (Table 1).
Interestingly, not all cell cultures of the 31 patients with clinically
overt metastases harboured CK-positive cells: eight cases were
negative for culture (26%) (Table 2). Cultures were also negative in
four cases of clinical metastatic disease with positive initial
screening (see Table 2).
Correlation with clinical outcome
The median follow-up was 23 months. Thirteen deaths have
occurred, all in metastatic patients. The median survival has not
been reached in view of this short median follow-up. Statistical
analysis (log-rank test) showed that primary detection of CK-
positive cells in 34 patients was not significantly correlated with an
increased risk of cancer-related death (P¼0.15) (Figure 3B). Forty
patients had positive culture screening and 12 of them have died.
Two of these patients had a negative primary screening. The
difference in overall survival between the CK-positive group and
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Meier analysis (P¼0.04) (Figure 3A).
DISCUSSION
The present study investigates the clinical relevance of the extent
of in vitro expansion of CK-positive cells present in bone marrow
aspirate, under adapted conditions published by Pantel et al (1995)
and Solakoglu et al (2002). Compared to Solakoglu’s study, our
study included more metastatic patients and a smaller total
number of patients. However, our series is homogeneous in terms
of the type of cancer, as all patients presented breast cancer, in
contrast with Solakoglu’s study which included a very hetero-
geneous population including prostate, renal and breast cancers.
The detection of isolated tumour cells in the bone marrow of
patients with metastatic breast cancer has also been demonstrated
to be a factor of poor prognosis (Janni et al, 2000).
Cultured bone marrow cells may nonspecifically express CK
detected by anticytokeratin antibodies. Pantel et al (1995) using
the same antibody as that used in our study excluded this
possibility by using a negative control and confirmation of tumour
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Figure 1 Example of automated detection and montage of CK-positive cells in vitro expanded bone marrow sample of two stage IV patients (patient’s
344 and 490).
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eliminated in our series by staining the same number of control
slides under the same conditions with a nonrelevant primary
antibody (anti-FITC) for each case.
The number of in vitro expanded CK-positive cells was not
correlated with the number of CK-positive cells on bone marrow
aspirates. Pantel et al (1995) demonstrated the variable growth
kinetics of these tumours. The number of CK-positive cells on
culture screening may therefore not be related to the various bone
marrow loads observed among individual patients, but could
reflect the in vitro proliferative potential of these cells. The
concentration of tumour cells in culture can then increase as a
result of proliferation of tumour cells in culture of nonadherent
bone marrow cells. A significant number of bone marrow samples
(14 patients, 23%), negative on primary screening, became positive
after cell culture. This could be explained by the number of bone
marrow cells plated in culture flasks (10 to 30 10
6) that is higher
than the number of bone marrow cells examined on primary
screening (3 10
6). These cultures were grown under almost
limiting dilution conditions, that is, fewer than 10 tumour cells
were plated per flask, indicating that micrometastatic cells can
inherit a strong growth potential. Culture techniques could
increase the sensitivity of detection of occult tumour cells in
human bone marrow about 100-fold (Joshi et al, 1990). In a
previous study published by Ross et al (1993), ICC detection of
tumour involvement in bone marrow and peripheral blood stem
cell collections (PBSC) was significant with in vitro clonogenic
growth (Po0.0001). The incidence and viability of tumour cell
involvement in PBSC and bone marrow were studied in 48 patients
with locally advanced or metastatic breast cancer enrolled on high-
dose chemotherapy programmes. In culture experiments, clono-
genic tumour colonies grew in 21 out of 26 immunocytochemically
positive specimens. No tumour colony growth was detected in 30
out of 32 immunochemically negative specimens. In contrast, in
our study, several cases positive on primary screening were
negative after culture expansion. This could indicate that the cells
initially detected were unable to proliferate, but it could also be
due to failure of trypsinisation, leaving the tumour cells adherent
Table 2 Comparison of detection of CK-positive cells at initial screening and detection of CK-positive cells
grown in culture of bone marrow, in 29 primary patients (stage I–III), in 31 metastatic patients (stage IV) and
in the whole population (N¼60)
CK-positive cells
grown in culture
Negative primary
screening
Positive primary
screening
Primary Negative 8 4 12 (41%)
(N¼29) Positive 10 7 17 (59%)
18 (62%) 11 (38%) P¼0.66
Metastatic Negative 4 4 8 (26%)
(N¼31) Positive 4 19 23 (74%)
8 (26%) 23 (74%) P¼0.08
All patients Negative 12 8 20 (33.3%)
(N¼60) Positive 14 26 40 (66.6%)
26 (43.3) 34 (56.6) P¼0.065
Table 3 Correlation between UICC stage of the patients and number of CK-positive cells detected on
3 10
6 MNCs on initial screening. Lack of correlation between UICC stage of the patients and extent of in
vitro expansion of CK-positive cells
CK-positive primary screening CK-positive culture screening
Stage Number of cells/3 10
6 7s.d. Number of cells/10
6 7s.d.
II (n¼17) 1.5 3.9 10.2 24.1
III (n¼12) 2 5.7 11.2 17.6
IV (n¼31) 105.8 247.7 31.2 89.1
Total (n¼60) 55.5 184.3 21.3 66.0
Kruskal–Wallis P¼0.0013 P¼0.21
Figure 2 Cells in mitosis in a cluster detected in a stage IIB patient at
primary screening.
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also not completely reflect the contents of the culture flask. In
comparison with native tumour cells, cells shed from a tumour
were less clonogenic, more apoptotic and less tumorigenic (Swartz
et al, 1999). The degree of anchorage-independent growth of
tumour cells can predict their biological behaviour and metastatic
potential in vivo (Li et al, 1989; O’Sullivan et al, 1999).
We found a statistically significant relationship between the in
vitro extent of expansion of micrometastatic tumour cells and
patient outcome, essentially the survival of metastatic patients. We
did not observe any difference in survival or disease-free survival
because of the small number of nonmetastatic patients in this
series and the short follow-up. All the patients who died during the
follow-up were the metastatic patients. The cells that were
expanded may be sourced from the secondary tumour rather than
the primary. However, the extent of in vitro expansion of CK-
positive cells was a better prognostic indicator than simple
detection of these cells in bone marrow samples. Similar data
have been obtained for the expression of HER2 and urokinase
plasminogen activator receptor in bone marrow (Heiss et al., 1995;
Allgayer et al, 1997; Braun et al, 2001). Bone marrow cells were
cultured under specific conditions: cultures were performed under
hypoxic conditions (4% O2 instead of 20% O2), as hypoxia
stimulates carcinoma invasiveness by upregulating uPAR expres-
sion on the cell surface (Graham et al, 1999).
Analysis of cultured micrometastatic tumour cells could provide
a greater number of CK-positive cells available for subsequent
molecular analyses. Analysis of cultured CK-positive cells could
contribute to the identification of the metastatic stem cells
responsible for the formation of overt metastases. Cell lines have
also been established from bone marrow micrometastases (Rye
et al, 1996; Putz et al., 1999), but the culture process could lead to
selection of those cell clones that adapt best to the culture
conditions.
In all the large published series, not all patients with CK-positive
cells in bone marrow develop clinical metastases. CK-positive cells
appear to have a heterogeneous phenotype (Braun et al, 1999) and
their genotype has also been shown to be heterogeneous (Klein
et al, 2002). Klein et al reported a high genetic variability in
minimal residual cancer, particularly in terms of chromosomal
imbalances by using comparative genomic hybridisation. Two
individual tumour cells from the same patient may not be
identical, supporting the concept of genetic instability.
Solakoglu et al (2002) has suggested that larger prospective
clinical trials be performed in order to confirm the clinical
relevance of the in vitro extent of expansion of CK-positive cells.
This type of trial would be very difficult to organise in view of the
very specific culture conditions and the fairly long time required
for detection of tumour cells in culture. However, a better
understanding of the biology of micrometastatic cells is necessary
to increase the precision of detection in bone marrow.
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